Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke

NCT07483281 is registered in ClinicalTrials.gov with China-Japan Union Hospital as lead sponsor.

NCT NCT07483281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07483281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
Lead sponsor
China-Japan Union Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
June 18, 2028
Enrollment
220 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke